Related Experiment Video
Updated: Oct 17, 2025
06:48
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
35.4K
Aspirin use and prostate tumor angiogenesis
Benjamin C Fu1, Kai Wang2, Lorelei A Mucci2,3
1Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, 02115, USA. benfu@hsph.harvard.edu.
Cancer Causes & Control : CCC
|October 9, 2021
Summary
Regular aspirin use is linked to a less angiogenic prostate tumor profile, potentially reducing aggressive prostate cancer risk. Findings suggest aspirin use lowers cancer development via angiogenic mechanisms.
Area of Science:
- Oncology
- Vascular Biology
- Cancer Epidemiology
Background:
- Aspirin use is associated with a reduced risk of aggressive prostate cancer.
- The underlying biological mechanisms for this protective effect remain unclear.
Purpose of the Study:
- To investigate the association between regular aspirin use and prostate tumor angiogenesis.
- To explore how aspirin use influences key markers of tumor blood vessel formation.
Main Methods:
- Examined 572 men from the Health Professionals Follow-up Study reporting aspirin use.
- Assessed prostatectomy tumor blocks for microvessel size and irregularity using CD34 immunostaining.
- Employed multivariable linear regression to analyze differences in angiogenic biomarkers between aspirin users and non-users.
Main Results:
- Current aspirin users exhibited larger vessel area and diameter, with reduced vessel irregularity, indicating a less angiogenic tumor profile.
- Aspirin use duration and dosage correlated with increased vessel diameter.
- These angiogenic patterns were consistent across both low- and high-grade prostate cancers.
Conclusions:
- Findings suggest that aspirin use, especially current use, may inhibit prostate cancer development through modulation of angiogenic pathways.
- Aspirin's anti-angiogenic effects could be a key mechanism underlying its observed risk reduction for aggressive prostate cancer.
More Related Videos
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
282
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
282
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
753
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
753
01:10Mechanism of Angiogenesis
6.1K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.1K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
247
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
247
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K